Assembly Biosciences(ASMB) - 2025 Q4 - Annual Results

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – Exhibit 99.1 Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights – Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 – SOUTH SAN FRANCISCO, Calif. – March 19, ...